MORRISTOWN, N.J., Oct. 4 /PRNewswire/ -- Vicus Therapeutics, LLC, an oncology-focused, clinical-stage, biopharmaceutical company, today announced that John Maki, President and Chief Executive Officer, will participate in two panel discussions titled "Outsourcing: Best Practices and Lessons Learned from an Industry Perspective" and "Exit Strategies: Managing Risk and Reward" at BIOTECH 2007 on Monday, October 8, 2007. The sessions will run from 9:00 a.m. to 10:15 a.m. ET and from 12:30 p.m. to 1:45 p.m. ET, respectively, at the Loews Hotel in Philadelphia, PA.
About BIOTECH 2007
BIOTECH 2007, which is hosted by the BioNJ and Pennsylvania Bio, is designed to enhance the growth and development of the bioscience industry in the New Jersey and Pennsylvania regions. It is an opportunity for entrepreneurs, researchers and executives of emerging and large companies to network and share ideas, strategies and experiences.
About Vicus Therapeutics
Vicus Therapeutics is a privately-held, biopharmaceutical company
focused on the development of pharmaceutical product candidates for the
treatment of cancer supportive care indications with an initial focus on
cachexia. Vicus' strategy involves combining individual generic drugs that
have previously received regulatory approval for other indications and thus
have established post-marketing safety records. Vicus leverages its
proprietary science to design and patent novel drug combinations that work
together to reverse the body's maladaptive responses to cancer and its
treatment. Vicus' lead combination product candidate, VT-122, is in Phase 2
clinical trials for the treatment of cancer cachexia in patients with
advanced lung cancer. Additionally, Vicus has preclinical-stage combination
product candidates being evaluated for the treatment of oral mucositis and
cancer fatigue. Vicus' development programs are powered by its network of
leading clinical investigators and partners in the US, India and Japan.
|SOURCE Vicus Therapeutics, LLC|
Copyright©2007 PR Newswire.
All rights reserved